WebJan 5, 2024 · CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody ® technology platform, CytomX's goal is to transcend the limits of current cancer treatments. WebThe latest price target for . CytomX Therapeutics (NASDAQ: CTMX) was reported by Mizuho on March 28, 2024.The analyst firm set a price target for $2.00 expecting CTMX to rise to within 12 months ...
CytomX Therapeutics, Inc. (CTMX) Latest Stock Analysis
WebApr 9, 2024 · 8 Analysts CTMX Stock Overview CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. About the company Risk Analysis Negative shareholders equity Currently unprofitable and not forecast to become profitable over the next 3 years See All Risk Checks My Notes WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of “Hold” by Analysts BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of “Moderate Buy” by ... oreillys appleton wi
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue …
WebDXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security … WebMar 2, 2024 · InvestorsObserveris giving CytomX Therapeutics Inc (CTMX) an Analyst Rating Rank of 15, meaning CTMX is ranked higher by analysts than 15% of stocks. The average price target for CTMX is $3.564 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CTMX a Buy today. WebThe latest price target for CytomX Therapeutics ( NASDAQ: CTMX) was reported by Mizuho on Tuesday, March 28, 2024. The analyst firm set a price target for 2.00 expecting CTMX to rise to within 12 ... oreillys antifreeze prices